{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:39:33Z","timestamp":1790746773987,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K09859"],"award-info":[{"award-number":["16K09859"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H04211"],"award-info":[{"award-number":["17H04211"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08848"],"award-info":[{"award-number":["19K08848"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["18K08372"],"award-info":[{"award-number":["18K08372"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["Strategic Research Foundation at Private Universities"],"award-info":[{"award-number":["Strategic Research Foundation at Private Universities"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["Promotion Plan for the Platform of Human Resource Development for Cancer Project"],"award-info":[{"award-number":["Promotion Plan for the Platform of Human Resource Development for Cancer Project"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12185-019-02800-0","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T20:03:56Z","timestamp":1576613036000},"page":"200-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The role of calreticulin mutations in myeloproliferative neoplasms"],"prefix":"10.1007","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-5000","authenticated-orcid":false,"given":"Marito","family":"Araki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-9126","authenticated-orcid":false,"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"2800_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"2800_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u2013900.","journal-title":"N Engl J Med."},{"key":"2800_CR3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138.","journal-title":"Nature"},{"key":"2800_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"2800_CR5","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","journal-title":"PLoS Med."},{"key":"2800_CR6","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472\u20136.","journal-title":"Blood"},{"key":"2800_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459\u201368.","journal-title":"N Engl J Med."},{"key":"2800_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667\u201379.","journal-title":"Blood"},{"key":"2800_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391\u2013405.","journal-title":"N Engl J Med."},{"key":"2800_CR10","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379\u201390.","journal-title":"N Engl J Med."},{"key":"2800_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30:431\u20138.","journal-title":"Leukemia"},{"key":"2800_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","volume":"127","author":"C Marty","year":"2016","unstructured":"Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127:1317\u201324.","journal-title":"Blood"},{"key":"2800_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","volume":"6","author":"S Elf","year":"2016","unstructured":"Elf S, Abdelfattah NS, Chen E, Perales-Paton J, Rosen EA, Ko A, et al. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 2016;6:368\u201381.","journal-title":"Cancer Discov."},{"key":"2800_CR14","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1038\/bcj.2016.83","volume":"6","author":"KH Lim","year":"2016","unstructured":"Lim KH, Chang YC, Chiang YH, Lin HC, Chang CY, Lin CS, et al. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish. Blood Cancer J. 2016;6:e481.","journal-title":"Blood Cancer J."},{"key":"2800_CR15","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/leu.2016.308","volume":"31","author":"K Shide","year":"2017","unstructured":"Shide K, Kameda T, Yamaji T, Sekine M, Inada N, Kamiunten A, et al. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia. 2017;31:1136\u201344.","journal-title":"Leukemia"},{"key":"2800_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","volume":"131","author":"J Li","year":"2018","unstructured":"Li J, Prins D, Park HJ, Grinfeld J, Gonzalez-Arias C, Loughran S, et al. Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. Blood. 2018;131:649\u201361.","journal-title":"Blood"},{"key":"2800_CR17","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41388-018-0538-z","volume":"38","author":"KR Toppaldoddi","year":"2019","unstructured":"Toppaldoddi KR, da Costa CM, Bluteau O, Panneau-Schmaltz B, Pioch A, Muller D, et al. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. Oncogene. 2019;38:1651\u201360.","journal-title":"Oncogene"},{"key":"2800_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41408-019-0202-z","volume":"9","author":"K Shide","year":"2019","unstructured":"Shide K, Kameda T, Kamiunten A, Oji A, Ozono Y, Sekine M, et al. Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis. Blood Cancer J. 2019;9:42.","journal-title":"Blood Cancer J."},{"key":"2800_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1042\/BJ20081847","volume":"417","author":"M Michalak","year":"2009","unstructured":"Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J. 2009;417:651\u201366.","journal-title":"Biochem J."},{"key":"2800_CR20","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","volume":"127","author":"M Araki","year":"2016","unstructured":"Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 2016;127:1307\u201316.","journal-title":"Blood"},{"key":"2800_CR21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","volume":"127","author":"I Chachoua","year":"2016","unstructured":"Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu RI, Marty C, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127:1325\u201335.","journal-title":"Blood"},{"key":"2800_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/bjh.15266","volume":"181","author":"H Takei","year":"2018","unstructured":"Takei H, Edahiro Y, Mano S, Masubuchi N, Mizukami Y, Imai M, et al. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations. Br J Haematol. 2018;181:791\u2013802.","journal-title":"Br J Haematol"},{"key":"2800_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-016-0275-0","volume":"9","author":"L Han","year":"2016","unstructured":"Han L, Schubert C, Kohler J, Schemionek M, Isfort S, Brummendorf TH, et al. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J Hematol Oncol. 2016;9:45.","journal-title":"J Hematol Oncol."},{"key":"2800_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/leu.2016.280","volume":"31","author":"K Kollmann","year":"2017","unstructured":"Kollmann K, Warsch W, Gonzalez-Arias C, Nice FL, Avezov E, Milburn J, et al. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation. Leukemia. 2017;31:934\u201344.","journal-title":"Leukemia"},{"key":"2800_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41375-018-0181-2","volume":"33","author":"M Araki","year":"2019","unstructured":"Araki M, Yang Y, Imai M, Mizukami Y, Kihara Y, Sunami Y, et al. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation. Leukemia. 2019;33:122\u201331.","journal-title":"Leukemia"},{"key":"2800_CR26","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1182\/blood-2017-08-800896","volume":"131","author":"S Elf","year":"2018","unstructured":"Elf S, Abdelfattah NS, Baral AJ, Beeson D, Rivera JF, Ko A, et al. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood. 2018;131:782\u20136.","journal-title":"Blood"},{"key":"2800_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0564-z","author":"N Masubuchi","year":"2019","unstructured":"Masubuchi N, Araki M, Yang Y, Hayashi E, Imai M, Edahiro Y, et al. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface. Leukemia. 2019. https:\/\/doi.org\/10.1038\/s41375-019-0564-z.","journal-title":"Leukemia"},{"key":"2800_CR28","doi-asserted-by":"publisher","first-page":"35201","DOI":"10.18632\/oncotarget.26221","volume":"9","author":"M Araki","year":"2018","unstructured":"Araki M, Komatsu N. Mutant molecular chaperone activates cytokine receptor as a homomultimer. Oncotarget. 2018;9:35201\u20132.","journal-title":"Oncotarget."},{"key":"2800_CR29","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1182\/blood-2018-09-874578","volume":"133","author":"C Pecquet","year":"2019","unstructured":"Pecquet C, Chachoua I, Roy A, Balligand T, Vertenoeil G, Leroy E, et al. Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Blood. 2019;133:2669\u2013811.","journal-title":"Blood"},{"key":"2800_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2018-99-118348","volume":"132","author":"C Pecquet","year":"2018","unstructured":"Pecquet C, Balligand T, Chachoua I, Roy A, Vertenoeil G, Colau D, et al. Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in CALR mutated cells: perspectives for MPN therapy. Blood. 2018;132:4.","journal-title":"Blood."},{"key":"2800_CR31","doi-asserted-by":"publisher","first-page":"e122703","DOI":"10.1172\/jci.insight.122703","volume":"3","author":"E Pronier","year":"2018","unstructured":"Pronier E, Cifani P, Merlinsky TR, Berman KB, Somasundara AVH, Rampal RK, et al. Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight. 2018;3:e122703.","journal-title":"JCI Insight."},{"key":"2800_CR32","doi-asserted-by":"publisher","first-page":"9555","DOI":"10.1074\/jbc.RA118.002836","volume":"293","author":"N Arshad","year":"2018","unstructured":"Arshad N, Cresswell P. Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I. J Biol Chem. 2018;293:9555\u2013699.","journal-title":"J Biol Chem."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02800-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02800-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02800-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T01:20:24Z","timestamp":1608081624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02800-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2800"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02800-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"20 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}